---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-061717"
form_type: "8-K"
ticker: "BMRN"
cik: "0001048477"
company_name: "BIOMARIN PHARMACEUTICAL INC"
filed_at: "2026-09-14T13:26:20+00:00"
generated_at: "2026-09-14T13:27:07.991569+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# BioMarin appoints Robert Plenge to board, expanding to 11 members

## Summary
- Board increased from 10 to 11 members; Robert Plenge, M.D., Ph.D. appointed effective September 10, 2026.
- Plenge also named to Science and Technology Committee as an independent non-employee director.
- Granted RSUs valued at $400,000 under 2017 Equity Incentive Plan, vesting before next annual meeting.
- Eligible for standard non-employee director fees and committee retainers per April 21, 2026 proxy statement.

## SEC filing metadata
- accession: 0001628280-26-061717
- form_type: 8-K
- ticker: BMRN
- cik: 0001048477
- company_name: BIOMARIN PHARMACEUTICAL INC
- filed_at: 2026-09-14T13:26:20+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000162828026061717/0001628280-26-061717-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000162828026061717/bmrn-20260910.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-061717
- JSON: https://secwatch.observer/filing/0001628280-26-061717.json
- Plain text: https://secwatch.observer/filing/0001628280-26-061717.txt

## Key facts
- Executive change
  Robert Plenge, M.D., Ph.D. was appointed as Director at BIOMARIN PHARMACEUTICAL INC.
  - Action: appointed
  - Role: Director
  source text: appointed Robert Plenge, M.D., Ph.D., to the Board, to be effective September 10, 2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/1048477/000162828026061717/0001628280-26-061717-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.